<DOC>
	<DOCNO>NCT02338843</DOCNO>
	<brief_summary>This Phase 3 , double-blind , randomize study LJPC-501 ( angiotensin II ) adult patient diagnose catecholamine-resistant hypotension ( CRH ) conduct multiple center globally .</brief_summary>
	<brief_title>A Phase 3 Study LJPC-501 Patients With Catecholamine-Resistant Hypotension</brief_title>
	<detailed_description>Catecholamine-resistant hypotension ( CRH ) often fatal condition result underlying cause septic shock , inflammation due trauma , severe drug reaction . When condition occur , patient respond either volume expansion vasopressor treatment . However , patient require excessive dos vasopressor deem resistant . Angiotensin II peptide hormone naturally produce body regulate blood pressure via vasoconstriction sodium reabsorption . LJPC-501 ( angiotensin II ) develop treatment patient catecholamine-resistant hypotension ( CRH ) . This multi-site , randomize , double-blind , placebo-controlled study . Adult patient CRH , hospitalize ICU setting , may eligible participate . Approximately 315 patient enrol .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>1 . Adult patient ≥ 18 year age CRH , define require total sum catecholamine dose &gt; 0.2 mcg/kg/min minimum 6 hour maximum 48 hour , maintain MAP 5570 mmHg . 2 . Patients required central venous access arterial line present , expect remain present least initial 48 hour study . 3 . Patients require indwell urinary catheter present , expect remain present least initial 48 hour study . 4 . Patients must receive least 25 mL/kg crystalloid colloid equivalent previous 24hour period , adequately volume resuscitated opinion treat investigator . 5 . Patients must clinical feature highoutput shock meet one follow criterion . 1 . Central venous oxygen saturation ( ScvO2 ) &gt; 70 % ( either oximetry catheter central venous blood gas ) central venous pressure ( CVP ) &gt; 8 mmHg . OR 2 . Cardiac Index ( CI ) &gt; 2.3 L/min/1.73 m2 . Patient must meet 5a 5b eligible . 6 . Patient legal surrogate willing able provide write informed consent comply protocol requirement . 1 . Patients &lt; 18 year age . 2 . Any patient burn cover &gt; 20 % total body surface area ( TBSA ) . 3 . Patients Cardiovascular ( CV ) SOFA score ≤ 3 . 4 . Patients diagnose acute occlusive coronary syndrome require intervention . 5 . Patients venoarterial ( VA ) ECMO . 6 . Patients ECMO le 12 hour . 7 . Patients liver failure Model EndStage Liver Disease ( MELD ) score ≥ 30 . 8 . Patients history asthma currently experience bronchospasm require use inhale bronchodilator , mechanically ventilate . 9 . Patients acute mesenteric ischemia history mesenteric ischemic . 10 . Patients history , presence , highlysuspected aortic dissection abdominal aortic aneurysm . 11 . Patients require 500 mg daily hydrocortisone equivalent glucocorticoid medication stand dose . 12 . Patients Raynaud 's phenomenon , systemic sclerosis vasospastic disease . 13 . Patients expect lifespan &lt; 12 hour . 14 . Patients active bleeding AND anticipate need ( within 48 hour initiation study ) transfusion &gt; 4 unit pack red blood cell . 15 . Patients active bleeding AND hemoglobin &lt; 7g/dL condition would contraindicate serial blood sampling . 16 . Patients absolute neutrophil count ( ANC ) &lt; 1000 cells/mm3 . 17 . Patients know allergy mannitol . 18 . Patients current participate another interventional clinical trial . 19 . Patients know pregnant time Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>